Search

Author/Creator Readie, Aimee

1. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Issue 6 (13th December 2016)

Authors:
Braun, Jürgen; Baraliakos, Xenofon; Deodhar, Atul; Baeten, Dominique; Sieper, Joachim; Emery, Paul; Readie, Aimee; Martin, Ruvie; Mpofu, Shephard; Richards, Hanno B
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76:Issue 6(2017)
Page Start:
1070
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1). Issue 12 (December 2016)

Authors:
Deodhar, Atul A.; Dougados, Maxime; Baeten, Dominique L.; Cheng‐Chung Wei, James; Geusens, Piet; Readie, Aimee; Richards, Hanno B.; Martin, Ruvie; Porter, Brian
Journal:
Arthritis & rheumatology
Issue:
Volume 68:Issue 12(2016)
Page Start:
2901
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. LB0006 SUBCUTANEOUS SECUKINUMAB 300MG AND 150MG PROVIDES SUSTAINED INHIBITION OF RADIOGRAPHIC PROGRESSION IN PSORIATIC ARTHRITIS OVER 2 YEARS: RESULTS FROM THE PHASE 3 FUTURE-5 TRIAL. (June 2019)

Authors:
Mease, Philip J.; B.M. Landewé, Robert; Rahman, Proton; Tahir, Hasan; Singhal, Atul; Boettcher, Elke; Navarra, Sandra; Readie, Aimee; Mpofu, Shephard; Maria Delicha, Eumorphia; Pricop, Luminita; van der Heijde, Désirée
Journal:
Annals of the rheumatic diseases
Issue:
Volume 78(2019)Supplement 2
Page Start:
262
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. (30th May 2018)

Authors:
van der Heijde, Désirée; Braun, Jürgen; Deodhar, Atul; Baraliakos, Xenofon; Landewé, Robert; Richards, Hanno B; Porter, Brian; Readie, Aimee
Journal:
Rheumatology
Issue:
Volume 58:Number 3(2019)
Page Start:
388
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P250 Effect of secukinumab on radiographic progression through 2 years in patients with active PsA: end-of-study results from a Phase 3 study. (20th April 2020)

Authors:
Tahir, Hasan; Mease, Philip; Landewé, Robert; Rahman, Proton; Singhal, Atul; Böttcher, Elke; Navarra, Sandra; Readie, Aimee; Mpofu, Shephard; Delicha, Eumorphia-Maria; Pricop, Luminita; van der Heijde, Désirée
Journal:
Rheumatology
Issue:
Volume 59(2020)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Issue 6 (17th March 2018)

Authors:
Mease, Philip; van der Heijde, Désirée; Landewé, Robert; Mpofu, Shephard; Rahman, Proton; Tahir, Hasan; Singhal, Atul; Boettcher, Elke; Navarra, Sandra; Meiser, Karin; Readie, Aimee; Pricop, Luminita; Abrams, Ken
Journal:
Annals of the rheumatic diseases
Issue:
Volume 77:Issue 6(2018)
Page Start:
890
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. Issue 2 (30th July 2021)

Authors:
Mease, Philip J; Landewé, Robert; Rahman, Proton; Tahir, Hasan; Singhal, Atul; Boettcher, Elke; Navarra, Sandra; Readie, Aimee; Mpofu, Shephard; Delicha, Eumorphia Maria; Pricop, Luminita; van der Heijde, Desirée
Journal:
RMD open
Issue:
Volume 7:Issue 2(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. (5th October 2019)

Authors:
van der Heijde, Désirée; Mease, Philip J; Landewé, Robert B M; Rahman, Proton; Tahir, Hasan; Singhal, Atul; Boettcher, Elke; Navarra, Sandra; Zhu, Xuan; Ligozio, Gregory; Readie, Aimee; Mpofu, Shephard; Pricop, Luminita
Journal:
Rheumatology
Issue:
Volume 59:Number 6(2020)
Page Start:
1325
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗